Levi & Korsinsky, LLP Reminds Clovis Oncology, Inc. Shareholders of Filing of Class Action Lawsuit and Lead Plaintiff Deadline of January 18, 2016 – CLVS

NEW YORK, Dec. 09, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Clovis Oncology, Inc. (NASDAQ:CLVS) between May 20, 2014 and November 13, 2015.       

You are hereby notified that Levi & Korsinsky has commenced a securities class action lawsuit in the USDC for the District of Colorado. If you purchased or otherwise acquired Clovis Oncology securities between May 20, 2014 and November 13, 2015, your rights may be affected by this action. To get more information go to:

http://zlk.9nl.com/clovis-oncology-clvs

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) the New Drug Application (“NDA”) that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates; (2) Clovis’ Breakthrough Therapy designation submission contained immature data sets based primarily on unconfirmed responses; (3) Clovis presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses; (4) as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected; and (5) as a result of the foregoing, Clovis’ NDA was likely to be delayed and/or rejected by the FDA.

If you suffered a loss in Clovis Oncology you have until January 18, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor 
New York, NY 10004	
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com